Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
Novo Nordisk is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy copycats, with rare exceptions.
You are not logged in so some information on this page has been withheld. To see more, please log in.